Non-small cell lung cancer recurrent+1
Not recruitingStudy of CLN-081 tablets in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations who have previously received platinum chemotherapy
Study of CLN-081 tablets in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations who have previously received platinum chemotherapy
- Disease:Non-small cell lung cancer recurrentNon-small cell lung cancer metastatic
- Substances:Zipalertinib
Spain- Participants:18–64 years · 65+ years
- Substances:Zipalertinib
- Sponsor:Cullinan Pearl Corp.










